Public preview. Funding rounds, founders, and growth signals require a free account.

Monte Rosa Therapeutics, Inc. (GLUE)

Develops molecular glue degraders (MGDs) using the QuEEN platform to target undruggable proteins for cancer and immune diseases.

GrowthBiotechBoston, MA

Total raised

$143.0M

Last round

Equity

$95.0M · Mar 2021

Stage

Growth

Status

Active

Founders & team

Co-founder, CEO

Co-founder, CTO

Head of Engineering

Head of Sales

🔒

Free account unlocks founder names, LinkedIn profiles, and prior companies.

Web traffic

Search interest

Social followers

Glassdoor rating

News mentions

Gov contracts

🔒

Free account unlocks 5 full profiles per day. Pro removes the limit.

Get notified the moment Monte Rosa Therapeutics, Inc. (GLUE) files a new round, hires execs, or shows traction signals.

About this data

FlareSight surfaces funding data from SEC Form D filings within hours of submission. Browse our full startup funding database to find more recently funded companies.